Wird geladen...
Golimumab for the treatment of ulcerative colitis
Introduction: Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonis...
Gespeichert in:
| Veröffentlicht in: | Expert Opin Biol Ther |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490638/ https://ncbi.nlm.nih.gov/pubmed/28472597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1327576 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|